[Clinical trial of heptral in patients with chronic diffuse liver disease with intrahepatic cholestasis syndrome].
Heptral (S-adenosine-L-methionine) was given to 32 patients with chronic diffuse diseases of the liver and intrahepatic cholestasis. 16 of them had primary biliary cirrhosis (PBC). Phase I of the treatment lasted 16 days when the drug was injected intravenously in a dose 800 mg/day. It was followed by phase 2--1600 mg/day taken for 16 days. A response was registered in the majority of patients. They had relieved symptoms of asthenia, skin pruritus, jaundice. The patients with liver cirrhosis and chronic hepatitis exhibited a statistically significant fall in ALT, AST and GGTP. PBS patients showed insignificant lowering of cholesterol, bilirubin. No resistance was noted in repeated courses. Heptral tolerance was satisfactory.
Podymova
S D
SD
Nadinskaia
M Iu
MIu
D000293:Adolescent; D000328:Adult; D000368:Aged; D002780:Cholestasis, Intrahepatic / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D005260:Female; D005500:Follow-Up Studies; D019694:Hepatitis B, Chronic / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D019698:Hepatitis C, Chronic / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D007275:Injections, Intravenous; D008103:Liver Cirrhosis / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D008111:Liver Function Tests; D008297:Male; D008875:Middle Aged; D012436:S-Adenosylmethionine / Q000008:administration & dosage / Q000627:therapeutic use*; D013577:Syndrome; D016896:Treatment Outcome
D012436:S-Adenosylmethionine
Otsenka éffektivnosti preparata geptral u bol'nykh s khronicheskimi diffuznymi zabolevaniiami pecheni s sindromom vnutripechenochnogo kholestaza.